Proactiveinvestors Australia

ARTICLES

Archived Articles ►

MARKETS

  • ASX 200
  • 4975.40
  • -0.80
  • -0.02%
  • ASX All Ords
  • 5022.10
  • -3.50
  • -0.07%
  • SPI Futures
  • 4859.00
  • -64.00
  • -1.30%
  • Shanghai Index
  • 2763.49
  • 0.00
  • 0.00%

BREAKING NEWS

Archived Newswires ►

TWITTER: PROACTIVE INVESTORS

GLOBAL PROACTIVE INVESTORS

  • Monday, February 08, 2016
    China to add 5 new nuclear reactors each year until 2030
  • Currently nuclear power delivers 2% of China's energy needs, and the country remains the world's largest energy consumer. According to estimates in the draft 13th Five-Year Plan, China will probably add five to six nuclear reactors every year starting now, until 2030. That equates to over 110 new nuclear reactors in the next 15 years. By...
  • Monday, February 08, 2016
    Magnetite Mines looks into iron ore abyss and sees salvation
  • Magnetite Mines (ASX:MGT) is bucking the malaise in a difficult iron ore market with magnetite deposits in the Mawson Iron Province of South Australia gaining favour in Chinese circles and an innovative approach to potential future mining of the deposit. The Mawson Iron Province is located 250 kilometres NNE of Adelaide and may just be the...
  • Friday, February 05, 2016
    International Goldfields signs definitive agreement with WinterGarden
  • International Goldfields' (ASX:IGS) acquisition of an 85% stake in WinterGarden Biosciences, a Uruguayan medical cannabis company, is on track after signing a definitive agreement with Jardin de Invierno SA. IGS shares should gain a fillip on the news. Consideration is the issuance of IGS shares worth $8 million or 51% of the issued capital...
  • Friday, February 05, 2016
    Pharmaxis portfolio fires on all pistons as U.S. relations warm up
  • Pharmaxis (ASX:PXS) is tracking strong progress in the current quarter with a sharpened focus engagement with potential future big pharma partners for the company's LOXL2 inhibitor program targeting both the fatal lung disease idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). Chief executive Gary Phillips met...
  • Friday, February 05, 2016
    Cellmid appoints Elizabeth Masamune as director of subsidiary Advangen Inc
  • Cellmid Limited (ASX:CDY) has appointed Ms Elizabeth Masamune PSM, (MLS, BA Hons, GAICD) as a non-executive director of its wholly-owned subsidiary, Advangen Inc., Japan. Based in Tokyo, Ms Masamune will lead the strategy for évolis®, Cellmid's Australian FGF5 inhibitor hair growth product brand, to be launched in Japan and other parts of...
  • Friday, February 05, 2016
    TV2U International eyes reinstatement to ASX
  • TV2U International (ASX:TV2) formerly Galicia Energy Corporation will be reinstated to trading of its shares on 9 February 2016 on the ASX as a digital content enabler and technology provider after complying with Listing Rules. This follows an earlier reverse takeover of Galicia Energy. TV2U main product is a cloud-based entertainment over...
  • Thursday, February 04, 2016
    Oklo Resources granted exploration permit near 5Moz gold discovery
  • Oklo Resources (ASX:OKU) has now been granted exploration permit 2015-4606 covering the Moussala Gold Project in West Mali. This strategically located permit is within the prolific Kenieba Inlier 15 kilometres to the west of the company's Dandoko Project. Dandoko recently yielded 29 metres at 10.42g/t gold. Adding prospectivity to the area,...
  • Tuesday, February 09, 2016
    Dramatic Wall St falls buttressed by bargain hunters
  • After a bruising session where energy and tech stocks led declines on growth fears and weaker oil prices, Wall Street tickers managed to halve losses on bargain-hunting late on Monday
  • Tuesday, February 09, 2016
    Dramatic Wall St falls buttressed by bargain hunters
  • After a bruising session where energy and tech stocks led declines on growth fears and weaker oil prices, Wall Street tickers managed to halve losses on bargain-hunting late on Monday
  • Tuesday, February 09, 2016
    Partial halt to CTI BioPharma trial hurts shares
  • Shares of CTI BioPharma dropped by more than 60% after the company said the US Food and Drug Administration had placed a partial hold on the clinical studies for pacritinib after the incidence of “excess mortality”
  • Tuesday, February 09, 2016
    Drug trial blows up in BioCryst's face
  • BioCryst Pharmaceuticals faced an exit by investors on Monday as news of failure in trials of a new drug for a rare genetic disorder wiped two-thirds off its share price
Andrew McCrea is Sub Authorised Representative (SAR: 291331) of Proactive Investors Australia Pty Ltd
(ABN: 19 132 787 654) which is a Corporate Auhorised Representative (CAR: 413802) of RM Capital
Pty Ltd (AFSL: 221938).

Copyright © proactiveinvestors.com.au, 2012. All Rights Reserved